4/A: Elizabeth M. Anderson Corrects Form 4 Filing Regarding Revolution Medicines, Inc. Stock Awards

Elizabeth M. Anderson, a director of Revolution Medicines, Inc., files an amended Form 4 to correct previously reported amounts for restricted stock units and stock options granted on June 20, 2024.

Summary

• Elizabeth M. Anderson, a director at Revolution Medicines, Inc., filed an amendment to a previous Form 4 filing.
• The amendment corrects inaccuracies in the amounts reported for restricted stock units (RSUs) and stock options granted to her on June 20, 2024.
• The corrected filing shows that Anderson indirectly owns 26,990 shares of common stock through a trust.
• She also directly owns 20,073 shares of common stock, including 4,248 RSUs.
• Additionally, Anderson holds a stock option to buy 15,955 shares of common stock at an exercise price of $37.54, which vests on the earlier of June 20, 2025, or immediately prior to the Issuer's annual meeting of stockholders following the date of grant, subject to continued service.

Sentiment

Score: 7

Explanation: The document is a routine correction of a regulatory filing. It doesn't contain any information that would significantly impact the company's valuation, but transparency is generally viewed positively.

Future Outlook

The stock options vest on the earlier of the first anniversary of the grant date or immediately prior to the Issuer's annual meeting of stockholders following the date of grant, subject to the Reporting Person continuing in service through the vesting date.

Industry Context

Form 4 filings are standard disclosures required by the SEC for company insiders, such as directors and officers, to report transactions in their company's stock. These filings provide transparency to the market regarding insider activity.

Comparison to Industry Standards

• Stock option grants and RSU awards are common forms of compensation for directors in publicly traded companies, such as Revolution Medicines.
• The vesting schedules and exercise prices are generally in line with industry standards for similar biotech companies.
• Comparing Revolution Medicines' director compensation packages with those of companies like Amgen, Gilead Sciences, or Vertex Pharmaceuticals would provide a broader context.

Stakeholder Impact

• The correction of the filing ensures accurate information is available to shareholders and potential investors.
• The corrected information regarding stock ownership and potential dilution from stock options is relevant to shareholders.

Key Dates